As this is our first order by a private label customer, we are very excited. This agreement signifies the potential for further advances in the private label field and further follows our communicated financial expectations for our business.
Lone Henriksen, CEO CS MEDICA A/S
“The intermediate study results mark an important step for CS MEDICA and continues or strong track record for delivering impactful products. We are proud to share these results as the trial shows that the CANNASEN®CBD Arthritis Gel is proving to be both safe and efficient for patients.”
Lone Henriksen, CEO CS MEDICA A/S
“I am proud to announce that the issue of units prior to our listing was oversubscribed. The strong interest in our business strengthens us as we proceed with our work. I want to welcome the new shareholders on board as we move towards the listing on Spotlight Stock Market and onwards, continuously scaling the business while entering new markets and growing our product portfolio.”
CEO, Lone Henriksen
"We are happy to be approved for listing on Spotlight Stock Market. Our vision as a public company is to improve the wide public's life quality by offering effective and safe treatment solutions. We aim to be in constant development, exploring how CS MEDICA can support patients in their battle against disease, pain, and the sorrow it brings. The listing and forthcoming IPO are important steps for CS MEDICA as we continue with our work to reach our targets for the operation, primarily focusing on advancing across the European market, and continuing our research, and development activities. Moving ahead, we want to further our advancements working with carefully selected partners to establish our CANNASEN® product lines across European borders.”
Lone Henriksen, CEO CS MEDICA A/S
Pick a time period -
There are no items matching the current filter
There are no more items matching the current filter
Back to top